GTH - Genetron Holdings Limited
After hours:
| Previous close | 0.8741 |
| Open | 0.8973 |
| Bid | 0.8401 x 1300 |
| Ask | 0.9499 x 800 |
| Day's range | 0.8730 - 0.9000 |
| 52-week range | 0.7310 - 1.7500 |
| Volume | |
| Avg. volume | 23,890 |
| Market cap | 81.807M |
| Beta (5Y monthly) | 0.52 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2200 |
| Earnings date | 08 June 2023 - 09 June 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.35 |
GlobeNewswireGenetron Health Announces Receipt of Notification from Nasdaq
BEIJING, May 23, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) dated May 17, 2023, indicating that for the
- GlobeNewswire
Genetron Health Regains Compliance With Nasdaq Minimum Bid Price Requirement
BEIJING, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that the Company had received a notification letter (“Compliance Notice”) from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”), dated Jan
- GlobeNewswire
Genetron Health Reports Unaudited Second Quarter 2022 Financial Results
BEIJING, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited ("Genetron Health" or the "Company", NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the second quarter ended June 30, 2022. Recent Business Highlights Received College of American Pathologists (CAP) Accreditation for its laboratory
- GlobeNewswire
Genetron Health Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
BEIJING, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that the special committee (the “Special Committee”) of the Company’s Board of Directors (the “Board”) has retained Kroll, LLC (operating through its Duff & Phelps Opinions Practice
- GlobeNewswire
Genetron Health Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
BEIJING, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that its Board of Directors (the “Board”) has received a preliminary non-binding proposal letter dated August 21, 2022 (the “Proposal Letter”) from Mr. Sizhen Wang, co-founder, chair
Simply Wall St.Strong week for Genetron Holdings (NASDAQ:GTH) shareholders doesn't alleviate pain of one-year loss
Genetron Holdings Limited ( NASDAQ:GTH ) shareholders will doubtless be very grateful to see the share price up 36% in...
- GlobeNewswire
Genetron Health to Participate in the Goldman Sachs Healthcare Corporate Day
BEIJING, June 16, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that management will be participating in the virtual Goldman Sachs Healthcare Corporate Day. Genetron’s management team, Sizhen Wang, co-founder and Chief Executive Officer and Evan
- GlobeNewswire
Genetron Health Receives CAP Accreditation for its Maryland Laboratory
BEIJING, June 15, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced College of American Pathologists (CAP) Accreditation for its laboratory in Maryland, U.S. CAP Accreditation is designed to help laboratories maintain the accuracy of test results and